Groups

Prof. Dr. Gundram Jung:

Publications (selection of important publications)

_______________________________________________________________________________________________________________________________________________________________________________________________________

Hofmann M, Große-Hovest L, Bässler T, Pyz E, Bamberg ML, Aulwurm S, Bühring H-J, Schwartz K, Haen S, Schilbach K, Rammensee H-G, Salih HR and Jung G. Generation, selection and preclinical characterization of an Fc-optimized FLT3-antibody for the treatment of myeloid leukemia. Leukemia 26:1228-1237 (2012)

Große-Hovest L, Müller S, Minoia R, Wolf E, Zakhartchenko V, Wenigerkind H, Lassnig C, Besenfelder U, Müller M, Lytton SD, Jung G, Brem G. Cloned transgenic farm animals produce a bispecific antibody for T cell mediated tumor cell killing. Proc Natl Acad Sci USA 101,6858-6863 (2004)

Große-Hovest L, Hartlapp I, Marwan W, Brem G, Rammensee HG, Jung G. A recombinant bispecific single chain antibody induces targeted, supra-agonistic CD28 stimulation and tumor cell killing. Eur J Immunol 33, 1334-1340 (2003)

Jung G, Große-Hovest L, Krammer PH, Rammensee HG. Target cell restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments. Cancer Res 61,1846-1848 (2001)

Jung G, Brandl M, Eisner W, Fraunberger P, Reifenberger G, Schlegel U, Wiestler OD, Reulen HJ, Wilmanns W. Local immunotherapy of glioma patients with a combination of two bispecific antibody fragments and autologous lymphocytes: Evidence for in situ T-cell activation and therapeutic efficacy. Int J Cancer 91,225-230 (2001)

Jung G, Freimann U, v.Marschall Z, Reisfeld RA and Wilmanns W. Target cell induced T cell activation with bi- and trispecific antibody fragments. Eur J Immunol 21,2431-2435 (1991)

Jung G, Ledbetter JA, Müller-Eberhard HJ. Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc Natl Acad Sci USA 84,4611-4615 (1987)

Jung G., Honsik CJ, Reisfeld RA, Müller-Eberhard HJ. Activation of human peripheral blood mononuclear cells by anti-T3: Killing of tumor target cells coated with anti-target X anti-T3-conjugates. Proc Natl Acad Sci USA 83,4479-4483 (1986)